Simoa® for Early Detection of Blood-Based Biomarkers Associated with Alzheimer's Disease
App Note
Alzheimer‘s disease (AD) is a devastating illness that affects tens of millions of people worldwide. In addition to the emotional and financial burden on patients and caregivers, deaths from AD have doubled between 2000 and 2021, making AD the fith leading cause of death in the population age 65 and older. This highlights the urgent need for more efficient detection, monitoring, and treatment methods.
Molecular changes of AD can begin 20 years or more before symptoms arise, presenting substantial window of opportunity for disease detection. With recent advancement in disease-modifying therapies, early and accurate diagnosis of AD has become an increasing priority for developing treatments and improving patient outcomes.
Download our App Note to learn more.